Prosecution Insights
Last updated: August 06, 2026

Synergy Ip Group AG

13 pending office actions • 11 clients • 13 examiners • 10 art units • 0 of 13 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days

Quality Metrics (n=137 apps, methodology: how we score firms)

66.2%
Allowance Rate
n=137
+0.32σ
Allowance Rate (norm)
n=137
3.5
OAs to Allowance
n=47
-0.35σ
OAs to Allow (norm)
n=47
1017 days
Time to Allowance
n=47
+20.4pp
Interview Lift
n=137
35.2%
RCE Rate
n=137
0.0%
Appeal Rate
n=137

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=8 (min 20)
56.2%
§102 Overcome
n=32
43.9%
§103 Overcome
n=66
45.4%
§112 Overcome
n=55

Specialization & Scale

A61K, A61P, A61M
Top CPC Subclasses
49%
Top-3 CPC Share
n=137
0
Practitioners
n=137
Apps / Practitioner
n=137 (min 20)

Portfolio Summary

13
Total Pending OAs
7
Non-Final OAs
6
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (54%)
6
Medium (46%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (8%)
§103 only6 (46%)
Multi-statute (no §101)6 (46%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
69% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
8% of docket
3
Business / Other
23% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

130 h
Manual time on pending OAs
26 h
Time saved (low, 20%)
46 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GEMBEH, SHIRLEY V 1 63.1% +33.8%
TOTH, KAREN E 1 46.7% +25.4%
LIPPERT, JOHN WILLIAM 1 56.6% +41.3%
PINDERSKI, JACQUELINE M 1 26.7% +44.3%
JACKSON III, WALTER 1 100.0% +0.0%
LIU, XUE H 1 73.1% +12.4%
FAN, LYNN Y 1 47.5% +48.7%
STEVENS, MARK V 1 65.4% +42.0%
PETERS, ALEC JON 1 69.2% +53.8%
WELLES, COLMAN THOMAS 1 25.0% +49.0%

Hard Cases (8)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17198285 PEPTIDIC PROTEIN KINASE C INHIBITORS AND USES THEREOF LEE, JIA-HAI 9d
18773017 PORTABLE HANDHELD ELECTRONIC SPIROMETER TOTH, KAREN E
18294566 JOINT EXERCISE DEVICE AND JOINT EXERCISE METHOD USING EXERCISE EFFECT MAINTENANCE MODULE PINDERSKI, JACQUELINE M
18423327 3D ARTIFICIAL SKIN MODEL AND METHOD FOR PRODUCING THE SAME JACKSON III, WALTER
18558368 METHODS FOR PRODUCING NANOPARTICLE DISPERSIONS LIU, XUE H
18549476 TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE FAN, LYNN Y
18262183 ORAL GRANULES WITH COMBINATION OF EXTENDED-RELEASE AND QUICK-RELEASE MAGNESIUM, AND PRODUCTION METHODS STEVENS, MARK V
18317940 PHARMACEUTICAL COMPOSITIONS IN LYOPHILIZED FORM WELLES, COLMAN THOMAS

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18777616 TOPICAL COMPOSITION FOR ADMINISTRATION TO NAILS GEMBEH, SHIRLEY V
18773017 PORTABLE HANDHELD ELECTRONIC SPIROMETER TOTH, KAREN E
18698365 METHOD FOR PREPARING LIPID NANOPARTICLES LIPPERT, JOHN WILLIAM
18294566 JOINT EXERCISE DEVICE AND JOINT EXERCISE METHOD USING EXERCISE EFFECT MAINTENANCE MODULE PINDERSKI, JACQUELINE M
18558368 METHODS FOR PRODUCING NANOPARTICLE DISPERSIONS LIU, XUE H
18549476 TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE FAN, LYNN Y
18262183 ORAL GRANULES WITH COMBINATION OF EXTENDED-RELEASE AND QUICK-RELEASE MAGNESIUM, AND PRODUCTION METHODS STEVENS, MARK V
18000516 PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF PETERS, ALEC JON

Client Portfolio (11 clients)

Top Art Units

Art UnitApps
16151
16381
17421
17591
16131
16411
16121
17741
37831
16581

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18777616 TOPICAL COMPOSITION FOR ADMINISTRATION TO NAILS Mim Pharma GmbH GEMBEH, SHIRLEY V §103 Non-Final OA Pending Jul 19, 2024
18773017 PORTABLE HANDHELD ELECTRONIC SPIROMETER Healthup Spólka Akcyjna TOTH, KAREN E §103§112 Non-Final OA Pending Jul 15, 2024
18698365 METHOD FOR PREPARING LIPID NANOPARTICLES Leon-Nanodrugs GmbH LIPPERT, JOHN WILLIAM 1615 §103 Final Rejection Pending Apr 04, 2024
18294566 JOINT EXERCISE DEVICE AND JOINT EXERCISE METHOD USING EXERCISE EFFECT MAINTENANCE MODULE Es Healthcare Inc. PINDERSKI, JACQUELINE M §102§103§112 Non-Final OA Pending Feb 02, 2024
18423327 3D ARTIFICIAL SKIN MODEL AND METHOD FOR PRODUCING THE SAME Korea Advanced Institute Of Science And Technology JACKSON III, WALTER 1638 §102§103 Non-Final OA Pending Jan 26, 2024
18558368 METHODS FOR PRODUCING NANOPARTICLE DISPERSIONS Leon-Nanodrugs GmbH LIU, XUE H 1742 §103§112 Non-Final OA Pending Nov 01, 2023
18549476 TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINO ACID OXIDASE UNIVERSITEIT GENT FAN, LYNN Y 1759 §101§102§103 Non-Final OA Pending Sep 07, 2023
18262183 ORAL GRANULES WITH COMBINATION OF EXTENDED-RELEASE AND QUICK-RELEASE MAGNESIUM, AND PRODUCTION METHODS Hermes Pharma GmbH STEVENS, MARK V 1613 §103§112 Non-Final OA Pending Jul 19, 2023
18000516 PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND APPLICATION THEREOF Shanghai Bao Pharmaceuticals Co., Ltd. PETERS, ALEC JON 1641 §103 Final Rejection Pending May 26, 2023
18317940 PHARMACEUTICAL COMPOSITIONS IN LYOPHILIZED FORM Breath Therapeutics GmbH WELLES, COLMAN THOMAS 1612 §103 Final Rejection Pending May 16, 2023
18042460 JET IMPINGEMENT REACTOR Leon-Nanodrugs GmbH SORKIN, DAVID L 1774 §103 Final Rejection Pending Feb 22, 2023
17776226 ADAPTER FOR A DRUG MIXING AND INJECTION SYSTEM Activoris Medizintechnik GmbH PAZ ESTEVEZ, GUILLERMO G 3783 §103 Final Rejection Pending May 12, 2022
17198285 PEPTIDIC PROTEIN KINASE C INHIBITORS AND USES THEREOF UNIVERSITE DE GENEVE LEE, JIA-HAI 1658 §103§112 Final Rejection 9d Pending Mar 11, 2021

Managing Synergy Ip Group AG's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month